Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
Carolina Schinke, Eileen M. Boyle, Cody Ashby, Yan Wang, Valeriy V. Lyzogubov, Christopher P. Wardell, Pingping Qu, Antje Hoering, Shayu Deshpande, Katie R. Ryan, Sharmilan Thanendrarajan, Meera Mohan, Naveen Yarlagadda, Maliha Khan, Samrat Roy Choudhury, Maurizio Zangari, Frits van Rhee, Faith E. Davies, Bart Barlogie, Gareth J. Morgan, Brian A. Walker
Abstract
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma (MM) that is characterized by the presence of ≥20% circulating plasma cells. Overall survival remains poor despite advances of anti-MM therapy. The disease biology as well as molecular mechanisms that distinguish pPCL from non-pPCL MM remain poorly understood and, given the rarity of the disease, are challenging to study. In an attempt to identify key biological mechanisms that result in the aggressive pPCL phenotype, we performed whole-exome sequencing and gene expression analysis in 23 and 41 patients with newly diagnosed pPCL, respectively. The results reveal an enrichment of complex structural changes and high-risk mutational patterns in pPCL that explain, at least in part, the aggressive nature of the disease. In particular, pPCL patients with traditional low-risk features such as translocation t(11;14) or hyperdiploidy accumulated adverse risk genetic events that could account for the poor outcome in this group. Furthermore, gene expression profiling showed upregulation of adverse risk modifiers in pPCL compared to non-pPCL MM, while adhesion molecules and extracellular matrix proteins became increasingly downregulated. In conclusion, this is one of the largest studies to dissect pPCL on a genomic and molecular level.